Sequana Medical NV, at the forefront of addressing fluid overload in liver disease, heart failure, and cancer, has unveiled a newly published study in the esteemed Kidney Medicine journal. The publication reviews the company’s innovative DSR 2.0 technology featured in their Direct Sodium Removal paradigm—a proposed treatment for cardiorenal syndrome and overcoming diuretic resistance in heart failure cases.
According to Dr. Jeffrey Testani, an Associate Professor at Yale University, “The manuscript outlines the transition from pre-clinical phases to the initial human trials of a first-of-its-kind solution purposed for sodium extraction in patients. While current peritoneal solutions prioritize clearing toxins from the blood, DSR 2.0 specifically addresses the urgent clinical necessity of eliminating excess salt and fluid. Our findings are remarkable, showing approximately four times more sodium removal through DSR 2.0 compared to a typical commercial solution. This advancement could markedly improve care for patients battling diuretic resistant cardio-renal syndrome.”
Ian Crosbie, the CEO of Sequana Medical, expressed satisfaction with the publication showcasing the improved safety and effectiveness of their DSR 2.0 over dextrose-based methods. He stated, “This research builds on the clinical validation previously released in the European Journal of Heart Failure, where DSR was considered a promising drug treatment for diuretic resistance and cardiorenal syndrome in heart failure, as demonstrated with our DSR 1.0. Our findings from the initial US MOJAVE study participants utilizing our enhanced DSR 2.0 back the superior results presented in this excellent manuscript. We foresee DSR’s potential for drastically reducing the reliance on loop diuretics for extended periods post-treatment, representing a significant advancement in therapeutic solutions and addressing a major contributor to healthcare expenditures.”
The publication elaborates on both pre-clinical and clinical trials aimed at optimizing a solution for sodium and water extraction, building on earlier concept validation studies detailed in Circulation. These earlier studies showed that DSR 1.0 quadrupled sodium removal effectiveness compared to standard peritoneal dialysis solutions. Human trials revealed that one liter of DSR 1.0, with a two-hour dwell, extracted an average of 4.5g of sodium with a net ultrafiltration volume of 700mL. In contrast, the recent study reveals that 0.5L of DSR 2.0 during a 24-hour dwell accomplished the removal of ~9g of sodium alongside a net ultrafiltration volume of 2,500mL.